Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Nektar Therapeutics
company
About
Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.
- 501 - 1000
Highlights
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $25M
- Industries
- Biotechnology,Chemical,Health Care,Therapeutics
- Founded date
- Jan 1, 1990
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$25M
Nektar Therapeutics has raised a total of
$25M
in funding over 2 rounds. Their latest funding was raised on
Aug 28, 2013 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 28, 2013 | Post-IPO Equity | $25M | 1 |
AstraZeneca
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Nektar Therapeutics is funded by 1 investors.
AstraZeneca
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
AstraZeneca
|
Yes | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
